amoxicillin and s 1743
amoxicillin has been researched along with s 1743 in 156 studies
Research
Studies (156)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 43 (27.56) | 29.6817 |
| 2010's | 85 (54.49) | 24.3611 |
| 2020's | 28 (17.95) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M | 1 |
| Fennerty, MB; Laine, L; Levine, JG; Osato, M; Probst, P; Suchower, L; Sugg, J | 1 |
| Bartuzi, Z; Dite, P; Hasselgren, G; Kleczkowski, D; Kryszewski, A; Larkö, A; Rudzinski, J; Tulassay, Z; Wrangstadh, M | 1 |
| Kas'ianenko, VI; Vasil'ev, IuV | 1 |
| Boon, YH; Cheng, CS; Chian, LC; Chiu, TC; Kaushik, S; Vu, C | 1 |
| Go, MF | 1 |
| Vasil'ev, IuV | 1 |
| Chen, TW; Cheng, HC; Hunag, SF; Kao, AW; Lu, CC; Sheu, BS; Wu, JJ | 1 |
| Johansen, JK; Krogfelt, KA; Ladefoged, K; Myrhøj, T; Sehested, A | 1 |
| Cammarota, G; Candelli, M; Cazzato, IA; Cremonini, F; Finizio, R; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Pignataro, G; Santoro, M; Zocco, MA | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Chen, YH; Li, HY; Wang, H; Wang, WM | 1 |
| Domínguez-Martín, A; Domínguez-Muñoz, A; Gisbert, JL; Gisbert, JP; Marcos, S | 1 |
| Pan, Y; Xiao, SD; Zhang, L; Zheng, Q | 1 |
| Chen, JL; Chen, WC; Cheng, JS; Hsu, PI; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Tsay, FW; Tseng, HH; Wu, CJ; Yamaoka, Y; Yu, HC | 1 |
| Antos, D; Bästlein, E; Bayerdörffer, E; Buchner, M; Haferland, C; Hänel, C; Lehn, N; Meier, E; Schneider-Brachert, W; Stolte, M; Trump, F | 1 |
| Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Song, IS | 1 |
| Hassan, C; Morini, S; Panarese, A; Piglionica, D; Scaccianoce, G; Zullo, A | 1 |
| Andersson, T; Hassan-Alin, M; Liljeblad, M; Niazi, M; Persson, BA; Röhss, K | 1 |
| Ferrara, EC; Manes, G; Porro, GB | 1 |
| Bästlein, E; Bayerdörffer, E; Hansky, K; Jacobs, E; Kirsch, C; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Schneider-Brachert, W; Stolte, M | 1 |
| Alberer, M; Antos, D; Arenz, T; Buderus, S; Kappler, M; Koletzko, S; Rüssmann, H | 1 |
| Capodicasa, S; Cappello, G; Coraggio, D; Grossi, L; Marzio, L | 1 |
| Abudayyeh, S; El-Zimaity, HM; Graham, DY; Hoffman, J; Opekun, AR; Reddy, R | 1 |
| Chen, A; Hsu, PI; Lai, KH; Lo, GH; Tsay, FW; Tseng, HH; Wang, WM; Wu, CJ; Wu, DC; Wu, IC; Wu, JY | 1 |
| Bellini, M; Ciancia, E; Costa, F; Cristiani, F; de Bortoli, N; Leonardi, G; Marchi, S; Merlo, A; Mumolo, MG; Ricchiuti, A; Rossi, M; Santi, S | 1 |
| Aiello, F; Brandimarte, G; Elisei, W; Giorgetti, GM; Modeo, ME; Tursi, A | 1 |
| Tang, Y; Wen, FQ; Xiang, L; Zuo, WH | 1 |
| Chen, TA; Chuah, SK; Hsu, PI; Lai, KH; Lin, WS; Lo, GH; Peng, NJ; Tsay, FW; Tseng, HH; Wu, CJ | 1 |
| But, D; Chan, AO; Chan, CK; Chan, P; Cheung, TK; Chu, KM; Fung, J; Hsu, A; Hung, I; Wong, BC; Yee, YK; Yuen, MF | 1 |
| Jung, HC; Kang, JM; Kim, JS; Kim, N; Kim, YR; Lee, DH; Park, YS; Song, IS | 1 |
| Bair, MJ; Chang, WH; Chen, JJ; Hsu, PI; Kuo, FC; Lu, CY; Wang, TE; Wang, WM; Wu, DC; Wu, IC; Wu, JY; Yu, FJ | 1 |
| Cho, YK; Choi, HS; Hwang, SJ; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JS; Sohn, CI | 1 |
| Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B | 1 |
| Butruk, E; Dite, P; Eklund, S; Engstrand, L; Gottlow, M; Malfertheiner, P; Nagy, P; Sjölund, M; Stolte, M; Tchernev, K; Tulassay, Z; Wong, BC; Wrangstadh, M | 1 |
| Chang, IJ; Jung, HC; Kang, JM; Kim, JS; Kim, N; Lee, DH; Park, YS; Song, IS | 1 |
| Dragomir, D; Hurduc, V; Plesca, D; Sajin, M; Vandenplas, Y | 1 |
| Di Caro, S; Franceschi, F; Gasbarrini, A; La Rocca, E; Mariani, A; Masci, E; Raimondo, D; Testoni, A; Thompson, F | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Chang, LL; Chen, A; Hsu, PI; Hu, HM; Jan, CM; Kuo, CH; Kuo, FC; Li, CJ; Tsai, PY; Wang, SW; Wang, WM; Weng, BC; Wu, DC; Wu, IC; Yu, FJ | 1 |
| de Boer, WA; Janssen, MJ; Schrauwen, RW | 1 |
| Hwang, TJ; Jung, HC; Kim, N; Lee, BH; Lee, DH; Nam, RH; Park, YS; Song, IS; Yoon, H | 1 |
| Amitrano, M; Grossi, L; Manzoli, L; Marzio, L; Sacco, F; Spezzaferro, M | 1 |
| But, D; Chan, CK; Chan, FS; Chan, P; Cheung, TK; Chu, KM; Gu, Q; Hsu, A; Hung, IF; Leung, S; Seto, WK; Tong, TS; Wong, BC; Wong, SY | 1 |
| Andrei, F; Grasso, E; Lionetti, R; Pallone, F; Paoluzi, OA; Ranaldi, R; Stroppa, I; Tosti, C; Visconti, E | 1 |
| Abudayyeh, S; Graham, DY; Javed, SU; Keihanian, S; Opekun, AR | 1 |
| Butruk, E; Dítê, P; Eklund, S; Engstrand, L; Gottlow, M; Herszényi, L; Malfertheiner, P; Nagy, P; Stolte, M; Tchernev, K; Tulassay, Z; Wong, BC; Wrangstadh, M | 1 |
| Abbas, Z; Abid, S; Jafri, W; Khalid, A; Khan, R; Naz, S; Yakoob, J | 1 |
| Cristofari, F; De Francesco, V; Hassan, C; Manes, G; Scaccianoce, G; Zullo, A | 1 |
| Chan, AK; Chan, FK; Chau, TS; Lee, KK; Lee, VW; Ling, TK; Waye, MM | 1 |
| Chang, JJ; Chang, LC; Chen, LW; Chien, RN; Fang, KM | 1 |
| Ahmed, MR; Youssef, TF | 1 |
| Xiao, L; Xu, C; Zou, H | 1 |
| Li, Y; Pan, X; Qian, B; Qiu, Y; Shi, R; Tang, Q; Yao, L; Zhang, G | 1 |
| Jung, HC; Kim, JY; Kim, N; Park, JH; Park, SY; Song, IS; Yoon, H | 1 |
| Boyanova, L; Cabrita, AM; de Carvalho, JN; Gonçalves, TM; Medeiros, JA; Pereira, AM; Pereira, MI | 1 |
| Bontem, P; Buderus, S; Iwańczak, B; Kalach, N; Koletzko, S; Liptay, S; Martínez-Gómez, MZ; Roma-Giannikou, E; Schwarzer, A; Urruzuno, P; Wenzl, TG | 1 |
| Chen, A; Hsu, PI; Kuo, CH; Lai, KH; Tsay, FW; Tseng, HH; Wang, SW; Wu, DC | 1 |
| Chiu, YC; Chuah, SK; Hsu, PI; Hu, ML; Hu, TH; Kuo, CM; Tai, WC; Wu, DC; Wu, KL | 1 |
| Berning, M; Jebens, C; Knoth, H; Krasz, S; Kuhlisch, E; Laass, MW; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Neumeyer, M; Schneider-Brachert, W; Stolte, M; Vieth, M; Zekorn, C | 1 |
| Fragou, P; Georgopoulos, S; Karatapanis, S; Laudi, F; Lisgos, P; Papantoniou, N; Papastergiou, V; Skorda, L; Spiliadi, C; Xirouchakis, E | 1 |
| Emer, O; Kadayifci, A; Kantarcioglu, M; Ozcan, A; Polat, Z; Uygun, A | 1 |
| Compare, D; Federico, A; Gravina, AG; Iovene, MR; Loguercio, C; Marmo, R; Miranda, A; Nardone, G; Pilloni, PA; Ricciardiello, L; Rocco, A; Romano, M | 1 |
| Başer, O; Emer, O; Kadayifci, A; Kantarcioğlu, M; Kılcıler, G; Ozcan, A; Polat, Z; Uygun, A | 1 |
| Wang, Z; Wu, S | 1 |
| Chang, KC; Chiou, SS; Chiu, KW; Chiu, YC; Chou, YP; Chuah, SK; Hsu, PI; Hu, ML; Hu, TH; Tai, WC; Wu, DC; Wu, KL | 1 |
| Barenys, M; Bory, F; Bujanda, L; Calvet, X; Calvo, MM; Castro-Fernández, M; García-Iglesias, P; Gisbert, JP; Lisozain, J; Sánchez-Delgado, J; Torra, S | 1 |
| Georgopoulos, S; Karatapanis, S; Laoudi, F; Lisgos, P; Papantoniou, N; Papastergiou, V; Spiliadi, C; Xirouchakis, E | 1 |
| Ashida, C; Higashida, A; Kuwada, T; Mamori, S; Mitsuoka, T; Senda, E; Suga, Y; Taki, M; Yamada, H | 1 |
| Georgopoulos, SD; Laoudi, F; Martinez-Gonzalez, B; Mentis, AF; Sgouras, DN; Spiliadi, C; Xirouchakis, E | 1 |
| Ben-Dor, D; Delgado, JS; Landa, E | 1 |
| Jo, HJ; Kim, MS; Kim, N; Kim, SE; Lee, DH; Park, YS; Shin, CM | 1 |
| But, DY; Hsu, AS; Hung, IF; Lam, FY; Leung, WK; Liu, KS; Seto, WK; Tong, T; Wong, SY | 1 |
| Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Jung, YS; Kim, ES; Kim, EY; Kim, KO; Kim, WJ; Kwon, JG; Lee, SH; Oh, MJ; Park, CS; Park, KS; Yang, CH | 1 |
| Graham, DY; Hsu, PI; Wang, WM; Wu, DC; Wu, JY | 1 |
| Mengnan, Z; Wei, Z; Wen, G; Yali, Z; Ying, L | 1 |
| Chen, M; He, L; Hou, X; Li, Z; Lin, S; Song, Z; Zhang, J; Zhou, L | 1 |
| Azmin, S; Hashim, H; Ibrahim, NM; Manaf, MR; Razlan, H; Tan, HJ; Yahya, NW | 1 |
| Almela, P; Angueira, T; Ariño, I; Barrio, J; Bermejo, F; Domínguez, JL; Domínguez-Muñoz, JE; Federico, A; Fernández, N; Fernandez-Bermejo, M; Ferrer-Barcelo, L; Gisbert, JP; Gomez, B; Gomez-Camarero, J; Gravina, AG; Lucendo, AJ; Marín, AC; Martin-Noguerol, E; Martorano, M; McNicholl, AG; Medina, E; Millastre, J; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Perez-Aisa, Á; Perona, M; Rodríguez-Tellez, M; Romano, M | 1 |
| Algaba, A; Angueira, T; Barrio, J; Bermejo, F; Castro-Fernández, M; Del Castillo, F; Domínguez, JL; Federico, A; Fernández-Salazar, L; Gisbert, JP; Gómez, B; Gómez, J; Gravina, AG; Herranz, M; Lucendo, AJ; Marín, AC; Martorano, M; McNicholl, AG; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Pabón, M; Romano, M; Solís-Muñoz, P; Velayos, B | 1 |
| Angueira, T; Ariño, I; Balboa, A; Barrio, J; Bermejo, F; Botargues-Bote, JM; Gisbert, JP; Gomez-Camarero, J; Gomez-Rodriguez, BJ; Herranz-Bachiller, MT; Huerta, A; Lucendo, AJ; Martin-Noguerol, E; McNicholl, AG; Modolell, I; Molina-Infante, J; O'Morain, C; Perez-Aisa, A; Rodriguez-Tellez, M | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Manzoli, L; Marzio, L | 1 |
| Cho, KB; Heo, J; Jang, BI; Jeon, SW; Jung, JT; Kim, HS; Kwon, JG; Lee, DW; Lee, SH; Park, JB; Park, KS; Yang, CH | 1 |
| Chen, MH; Hou, XH; Li, ZS; Lin, SR; Lu, JJ; Meng, LM; Xue, Y; Yan, XE; Zhang, J; Zhou, LY | 1 |
| Graham, DY; Lu, H | 1 |
| Gisbert, JP; Molina-Infante, J; Romano, M | 1 |
| Chiou, SS; Chiu, CH; Chiu, YC; Chuah, SK; Hu, ML; Hu, TH; Kuo, CH; Kuo, CM; Kuo, YH; Lee, CH; Liang, CM; Lu, LS; Tai, WC; Wu, KL; Yen, YH | 1 |
| Dechsukhum, C; Kaewpitoon, N; Kaewpitoon, S; Leeanansaksiri, W; Loyd, RA; Matrakool, L; Panpimanmas, S; Tongtawee, T | 1 |
| Choi, YJ; Kim, N; Kwon, YH; Lee, DH; Lee, JW; Lee, JY; Nam, RH; Suh, JH; Yoon, K | 1 |
| Chen, DF; Han, R; Lan, CH; Li, CX; Liao, ST; Wang, CH; Yang, J; Yang, YY | 1 |
| Bhatt, NR; Bhatt, R; Kakked, GA | 1 |
| Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L | 1 |
| Niv, Y | 1 |
| Forte, A; Jeverica, S; Šeruga, M; Stefanovič, M; Tepeš, B; Vujasinović, M | 1 |
| Bao, ZJ; Huang, YQ; Shi, DM; Xiang, P; Xiao, L; Yin, SM; Zhang, F; Zhang, GS | 1 |
| Chen, JH; Chua, CS; Hsu, YH; Huang, SY; Lee, HC; Liu, YH; Yang, KC | 1 |
| Amorena, E; Campillo, A; Kutz, M; LaIglesia, M; Ostiz, M | 1 |
| Georgopoulos, SD; Grivas, E; Kasapidis, P; Laoudi, F; Martinez-Gonzales, B; Mentis, A; Michopoulos, S; Petraki, K; Sgouras, D; Sotiropoulou, M; Spiliadi, C; Xirouchakis, E; Zampeli, E; Zografos, K | 1 |
| Castelli, V; Fiorini, G; Gatta, L; Ricci, C; Saracino, IM; Vaira, D; Vakil, N; Zullo, A | 1 |
| Chang, KC; Chiou, SS; Chiu, YC; Chou, YP; Chuah, SK; Hu, ML; Hu, TH; Kuo, CH; Kuo, CM; Lee, CH; Liang, CM; Lu, LS; Tai, WC; Wu, KL | 1 |
| Alvaro, D; Bellesia, A; De Francesco, V; Hassan, C; Ridola, L; Vaira, D; Zullo, A | 1 |
| Boemi, M; Bonazzi, P; Bonfigli, AR; Brandoni, G; Ceriello, A; Festa, R; Genovese, S; Olivieri, F; Spazzafumo, L; Testa, R | 1 |
| Hayakawa, Y; Hirata, Y; Koike, K; Sakitani, K; Serizawa, T; Shichijo, S; Suzuki, N; Yamada, A | 1 |
| Eguchi, T; Fujita, M; Fukuchi, T; Hashimura, H; Kanamori, A; Kano, C; Koizumi, A; Matsumoto, K; Momose, K; Okada, A; Shimoyama, K; Tsujimae, M; Yamashita, H | 1 |
| Ding, Y; Fu, W; Song, Z; Suo, B; Tian, X; Wang, L; Xue, Y; Zhou, L | 1 |
| Chiba, H; Chinda, D; Fukuda, S; Komai, K; Matsuzaka, M; Saito, Y; Sasaki, Y; Sawada, Y; Shimoyama, T | 1 |
| Chen, Y; Ke, L; Li, CJ; Liang, J; Ni, Z; Shang, L; Shi, YQ; Zhang, D; Zhang, LH; Zhu, SH | 1 |
| Algaba, A; Barrio, J; Calvet, X; Castro, M; Gisbert, JP; González-Santiago, JM; Herranz, MT; Molina-Infante, J; Puig, I | 1 |
| Chiba, D; Chinda, D; Fukuda, S; Kikuchi, H; Mikami, T; Nakagawa, S; Nakamura, M; Sawaya, M; Shimoyama, T | 1 |
| Hong, JB; Lu, NH; Luo, LY; Shu, X; Xie, C; Xie, Y; Ye, JF; Zhu, Y; Zhu, ZH | 1 |
| Adachi, T; Asakuma, Y; Kamata, K; Kashida, H; Komeda, Y; Kono, M; Kudo, M; Matsui, S; Minaga, K; Nagai, T; Nishida, N; Okamoto, A; Okamoto, K; Sakurai, T; Takenaka, M; Watanabe, T; Yamada, M; Yamao, K | 1 |
| Furuta, T; Horio, Y; Ichikawa, H; Kagami, T; Kato, A; Ohashi, N; Sahara, S; Sakao, Y; Sugimoto, K; Sugimoto, M; Yasuda, H | 1 |
| Fiorini, G; Gatta, L; Pavoni, M; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Carli, T; Kaliterna, N; Pintar, T | 1 |
| Gan, HY; Huang, YM; Peng, TL; Su, KH; Yang, RJ; Yao, LY; Zhao, LL | 1 |
| Bair, MJ; Chang, CC; Chang, CY; Chen, CC; Chen, MJ; Chen, PY; El-Omar, EM; Fang, YJ; Hsu, WF; Hsu, YC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Wu, MS; Yang, TH | 1 |
| Chen, Y; Du, Y; Hong, J; Huo, L; Lan, C; Li, X; Li, Y; Liu, W; Lu, H; Lu, N; Shu, X; Wang, H; Wang, J; Wang, W; Wang, X; Xie, Y; Xu, J; Zhang, G; Zhang, Z; Zhu, Y | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Shahbazi, S; Vahdat Shariatpanahi, Z | 1 |
| Chuah, SK; Hsu, CN; Hu, TH; Huang, PY; Kuo, CM; Kuo, YH; Lee, CH; Liang, CM; Lin, MT; Tai, WC; Wu, CK; Wu, KL; Yang, SC | 1 |
| Chen, Y; Li, J; Liu, L; Lu, B; Wang, J | 1 |
| Chen, DF; Fan, L; Lan, CH; Wang, TY; Wang, XW; Yang, J; Zhang, Y; Zhu, YJ | 1 |
| Kim, N; Yoon, K | 1 |
| Amato, A; De Francesco, V; Fiorini, G; Mogavero, G; Monica, F; Portincasa, P; Scaccianoce, G; Urban, F; Vaira, D; Vassallo, R; Zullo, A | 1 |
| De Francesco, V | 1 |
| Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y | 1 |
| Graham, DY; Ji, Y; Liang, X; Long, X; Lu, H; Luo, L; Yu, L | 1 |
| Kanai, T; Masaoka, T; Matsuzaki, J; Mori, H; Suzuki, H | 1 |
| Liu, W; Liu, Y; Wang, X; Wang, Y; Zhu, J | 1 |
| Chen, DF; Lan, CH; Wang, TY; Yang, J; Zhang, Y; Zhao, JT; Zhao, Z; Zhu, YJ | 1 |
| Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q | 1 |
| Zullo, A | 1 |
| Pan, L; Tang, G; Tang, Y; Wei, Z; Zhou, S; Zhu, H | 1 |
| Niu, Z; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
| Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A | 1 |
| Bozic, J; Kardum, G; Mestrovic, A; Pavicic Ivelja, M; Perkovic, N; Puljiz, Z; Tonkic, A; Vukovic, J | 1 |
| He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP | 1 |
| Chen, Y; Deng, X; Hou, X; Shi, Z; Ye, H; Yuan, H; Zhang, X | 1 |
| Chen, CC; Chiang, TH; Graham, DY; Lee, YC; Liou, JM; Shun, CT; Tseng, PH; Wu, MS | 1 |
| Alaa Eddin, K; Alassi, MW; Alhalabi, M; Cheha, K | 1 |
| Cha, JM; Jeon, JW; Kwak, MS; Yoon, JY | 1 |
| An, P; Chen, ZF; Ding, XW; Guan, JL; He, Q; Hu, YL; Li, PY; Long, H; Luo, HS; Wu, SS; Xiong, JG; Zhou, L | 1 |
| Daugule, I; Leja, M; Lielause, A; Park, JY; Paršutins, S; Poļaka, I; Rūdule, A; Sjomina, O; Stonāns, I; Vangravs, R | 1 |
| An, P; Chen, WG; Ding, XW; Han, YY; He, Q; Hu, YL; Li, PY; Lin, Y; Long, H; Wang, F; Zhang, ZY; Zhou, L | 1 |
| Gou, LZ; Han, TY; Li, XL; Lin, YM; Wang, C; Xu, HM; Yi, GR; Yu, Y; Yun, JW; Zhang, DK | 1 |
| Bi, H; Chen, X; Chen, Y; Han, S; Li, M; Lin, T; Liu, J; Lyu, T; Shi, Y; Wang, J; Wang, S; Yuan, D; Zhao, X | 1 |
| Li, CL; Lu, HP; Ren, XL; Song, ZQ; Suo, BJ; Tian, XL; Yao, XY; Zhang, H; Zhang, YX; Zhou, LY | 1 |
| He, XJ; Huang, XY; Li, DL; Li, DZ; Liu, G; Wang, W; Wang, XL | 1 |
| Du, Q; Han, Y; Li, Y; Lou, G; Lu, L; Wang, Y; Yan, H; Ye, J | 1 |
| Chen, J; Gui, Q; Liang, X; Lu, H; Su, W; Yu, D; Zhang, W; Zhu, C | 1 |
| Ellakany, WI; Ghazy, RM; Ismail, A; Kamal, A; Sherief, D | 1 |
| Chen, JN; Ding, ZH; Huang, Y; Liang, X; Lu, H; Luo, LS; Zhang, W | 1 |
| Li, C; Lu, H; Ren, X; Song, Z; Suo, B; Tian, X; Yao, X; Zhang, H; Zhang, Y; Zhou, L | 1 |
| Chen, ZY; Han, JL; Han, XY; Huang, XX; Lan, C; Li, PY; Li, YQ; Liu, DN; Mo, CY; Pan, J; Tan, Y; Tang, J; Wang, QY; Wu, DH; Yang, WZ | 1 |
| Chen, J; Ding, Z; Guo, Y; Han, Y; Huang, Y; Liang, X; Lu, H; Wang, J; Xu, P | 1 |
| Guo, Y; Hu, J; Lan, CH; Liu, HN; Liu, HQ; Liu, YX; Mei, H; Shi, Q; Su, NY; Wang, XW | 1 |
Reviews
3 review(s) available for amoxicillin and s 1743
| Article | Year |
|---|---|
Treatment and management of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Cardiovascular Diseases; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Rabeprazole; Stomach Neoplasms; Treatment Outcome | 2002 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2016 |
Trials
117 trial(s) available for amoxicillin and s 1743
| Article | Year |
|---|---|
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Stereoisomerism | 2000 |
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials.
Topics: Adult; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillin Resistance; Penicillins; Prospective Studies; Protein Synthesis Inhibitors; Proton Pump Inhibitors | 2000 |
One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Time Factors; Treatment Outcome | 2001 |
[Efficacy of the one week treatment with esomeprazole (nexium), clarythromycin, and amoxycillin of duodenal ulcer associated with Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Helicobacter pylori; Humans; Prospective Studies | 2002 |
[Pharmacoeconomic aspects of the 1-week eradication treatment of duodenal ulcer associated with Helicobacter pylori].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins | 2002 |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Gastric Mucosa; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mixed Function Oxygenases; Omeprazole; Risk | 2005 |
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Aza Compounds; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Patient Compliance; Prospective Studies; Quinolines; Tinidazole; Treatment Outcome | 2005 |
[Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 2005 |
Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 2005 |
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Patient Compliance; Peptic Ulcer; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2005 |
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Treatment Outcome | 2006 |
Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline; Treatment Outcome | 2006 |
Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Tinidazole; Treatment Outcome | 2006 |
Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Antagonism; Esomeprazole; Female; Half-Life; Helicobacter Infections; Humans; Male; Mixed Function Oxygenases | 2006 |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Rifabutin; Treatment Outcome | 2006 |
Randomized comparison of two rescue therapies for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Tetracycline | 2006 |
Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Probiotics; Prospective Studies; Treatment Outcome | 2007 |
Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Prospective Studies; Ranitidine; Tinidazole | 2007 |
[Different courses of esomeprazole-based triple therapy for Helicobactor pylori infection in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 2007 |
High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Pilot Projects; Prospective Studies; Treatment Outcome | 2007 |
Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Treatment Outcome | 2007 |
Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline | 2007 |
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Proton Pump Inhibitors; Rabeprazole | 2007 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult | 2008 |
Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Esomeprazole; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Secondary Prevention; Severity of Illness Index; Stomach Ulcer; Treatment Outcome; Young Adult | 2008 |
A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Probiotics; Prospective Studies; Proton Pump Inhibitors; Saccharomyces | 2009 |
Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Salvage Therapy; Young Adult | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Organometallic Compounds; Prospective Studies; Salvage Therapy; Tetracycline; Treatment Outcome; Young Adult | 2009 |
Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Urea; Young Adult | 2010 |
Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin | 2009 |
Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Tinidazole; Treatment Outcome; Young Adult | 2010 |
Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.
Topics: Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; United States | 2010 |
Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers.
Topics: Amoxicillin; Clarithromycin; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome | 2010 |
Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Male; Middle Aged; Mutation; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Rabeprazole; Urea | 2010 |
Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Treatment Outcome | 2010 |
Treatment of clinically diagnosed laryngopharyngeal reflux disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Egypt; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Laryngopharyngeal Reflux; Laryngoscopy; Male | 2010 |
[Effect of birid triple viable on peptic ulcer patients with Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus acidophilus; Male; Peptic Ulcer | 2010 |
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Ch
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Proton Pump Inhibitors; Rabeprazole | 2010 |
Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bifidobacterium; Breath Tests; Chi-Square Distribution; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus casei; Lactobacillus acidophilus; Male; Middle Aged; Moxifloxacin; Probiotics; Prospective Studies; Proton Pump Inhibitors; Quinolines; Republic of Korea; Streptococcus thermophilus; Time Factors; Treatment Outcome; Urease; Yogurt | 2011 |
Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus acidophilus; Male; Microbial Sensitivity Tests; Middle Aged; Peptic Ulcer; Probiotics; Single-Blind Method; Treatment Outcome; Urea; Young Adult | 2011 |
New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Europe; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lost to Follow-Up; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests | 2011 |
Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Polymorphism, Genetic; Tetracycline; Treatment Outcome | 2011 |
Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Treatment Outcome | 2011 |
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Salvage Therapy; Time Factors; Treatment Outcome; Urea; White People | 2011 |
Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Esomeprazole; Female; Greece; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Prospective Studies | 2012 |
Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Tinidazole; Treatment Outcome; Young Adult | 2012 |
Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline; Young Adult | 2012 |
Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Doxycycline; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Tetracycline; Treatment Outcome; Young Adult | 2012 |
Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Taiwan | 2012 |
Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome; Urea | 2013 |
Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Young Adult | 2013 |
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Free Survival; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Quinolines; Recurrence; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2013 |
Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Breath Tests; China; Clarithromycin; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Tetracycline; Treatment Outcome | 2014 |
Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2014 |
A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; China; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Tinidazole; Treatment Outcome; Young Adult | 2014 |
Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antiparkinson Agents; Breath Tests; Clarithromycin; Comorbidity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Urea | 2015 |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Young Adult | 2015 |
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2015 |
Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2015 |
Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Tinidazole; Young Adult | 2015 |
Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Combinations; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged | 2015 |
Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus delbrueckii; Male; Metronidazole; Middle Aged; Probiotics; Prognosis; Prospective Studies; Streptococcus; Young Adult | 2015 |
Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Republic of Korea; Tertiary Care Centers; Tetracycline; Young Adult | 2016 |
Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Health Knowledge, Attitudes, Practice; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Telephone; Time Factors; Treatment Outcome | 2015 |
Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome; Young Adult | 2016 |
Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Gastrectomy; Gastric Stump; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metaplasia; Middle Aged; Organometallic Compounds; Patient Positioning; Potassium Citrate; Treatment Outcome; Young Adult | 2016 |
Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyloric Antrum; Urea | 2016 |
A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2016 |
Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Time Factors; Treatment Outcome | 2016 |
Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biomarkers; Blood Glucose; Clarithromycin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Homeostasis; Host-Pathogen Interactions; Humans; Inflammation Mediators; Insulin; Insulin Resistance; Italy; Male; Middle Aged; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2016 |
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Medication Adherence; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Failure; Urea | 2017 |
Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Asian People; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2017 |
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Topics: Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Berberine; Bismuth; Body Mass Index; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Severity of Illness Index; Sex Factors | 2017 |
Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2017 |
Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies | 2017 |
Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Levofloxacin; Male; Middle Aged; Prevalence; Renal Dialysis; Treatment Outcome | 2018 |
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Exanthema; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2018 |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteriological Techniques; Breath Tests; Clarithromycin; Clinical Decision-Making; Doxycycline; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Predictive Value of Tests; Proton Pump Inhibitors; Taiwan; Tetracycline; Time Factors; Treatment Outcome | 2018 |
Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; China; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Humans; Male; Middle Aged; Treatment Outcome; Young Adult | 2018 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Patient Compliance; Tinidazole; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Research Design; Taiwan | 2019 |
Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome | 2019 |
Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Costs; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Treatment Outcome; Urea | 2019 |
Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Time Factors; Tinidazole; Treatment Outcome | 2019 |
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2019 |
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2019 |
10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; DNA Gyrase; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2020 |
Effects of addition of probiotic and/or bismuth to triple therapy of H. pylori and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Asian People; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Gene Frequency; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Polymorphism, Single Nucleotide; Probiotics; RNA, Ribosomal, 23S; Treatment Outcome | 2019 |
Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2020 |
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2020 |
Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Croatia; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2020 |
Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; China; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Endoscopy; Esomeprazole; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Microscopy, Electron, Transmission; Organometallic Compounds; Proton Pump Inhibitors; Salts | 2021 |
Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Syria; Tinidazole; Treatment Outcome; Young Adult | 2021 |
Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Treatment Failure; Treatment Outcome | 2021 |
Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2022 |
Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2022 |
High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Potassium Citrate; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2022 |
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2023 |
Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Nausea; Pectins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Peptic Ulcer; Pilot Projects | 2023 |
Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; COVID-19; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Pandemics; Proton Pump Inhibitors; Treatment Outcome | 2023 |
A randomized superiority clinical trial: metronidazole improved the efficacy of high-dose dual therapy in Helicobacter pylori rescue treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Potassium Citrate; Tetracycline | 2023 |
Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2023 |
Other Studies
36 other study(ies) available for amoxicillin and s 1743
| Article | Year |
|---|---|
One week regimen of esomeprazole based triple therapy is sufficient for duodenal ulcer healing and Helicobacter pylori eradication in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Prospective Studies; Treatment Outcome | 2002 |
Helicobacter pylori infection in Greenlandic patients with dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Esomeprazole; Greenland; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 2004 |
Eradication of Helicobacter pylori and dosages of esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2006 |
Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Patient Compliance; Prospective Studies; Treatment Outcome | 2006 |
Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Treatment Outcome; Urease | 2006 |
Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Infective Agents; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Fluoroquinolones; Gatifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome | 2006 |
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Outcome | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication.
Topics: Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Proton Pump Inhibitors | 2009 |
Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Microbial; Drug Therapy, Combination; Esomeprazole; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome | 2009 |
Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pakistan; Point Mutation; Prevalence; Risk Factors; RNA, Bacterial; RNA, Ribosomal, 23S; Treatment Failure; Urea; Virulence Factors; Young Adult | 2011 |
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Medication Adherence; Middle Aged; Ofloxacin; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Time Factors; Treatment Failure | 2010 |
High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged | 2012 |
Effectiveness of esomeprazole-based triple therapy of H. pylori in young patients in Japan.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Cohort Studies; Drug Therapy, Combination; Esomeprazole; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; Middle Aged | 2013 |
Granulomatous gastritis and Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Esomeprazole; Female; Gastritis; Granuloma; Helicobacter Infections; Helicobacter pylori; Humans; Symptom Assessment; Treatment Outcome | 2013 |
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Treatment Outcome | 2014 |
Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Neutrophil Infiltration | 2014 |
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Failure; Treatment Outcome; Urea | 2015 |
Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Esomeprazole; Female; Humans; Levofloxacin; Male; Proton Pump Inhibitors | 2015 |
Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance--authors' reply.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Esomeprazole; Female; Humans; Levofloxacin; Male; Proton Pump Inhibitors | 2015 |
Pneumobilia with gastric outlet obstruction.
Topics: Amoxicillin; Anti-Bacterial Agents; Biliary Tract Diseases; Clarithromycin; Esomeprazole; Gastric Bypass; Gastric Outlet Obstruction; Humans; Intestinal Fistula; Male; Middle Aged; Peptic Ulcer; Postprandial Period; Proton Pump Inhibitors; Treatment Outcome; Vomiting; Weight Loss | 2015 |
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome | 2016 |
The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bacterial Adhesion; Blueberry Plants; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Grape Seed Extract; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged | 2016 |
[10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Spain; Stomach Ulcer | 2016 |
Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Multivariate Analysis; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2018 |
Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2016 |
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
The Resolution of Helicobacter suis-associated Gastric Lesions after Eradication Therapy.
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Esomeprazole; Gastric Mucosa; Helicobacter heilmannii; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction | 2018 |
Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies | 2017 |
Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors; Tinidazole; Treatment Outcome | 2018 |
The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bariatric Surgery; Body Mass Index; Clinical Protocols; Drug Therapy, Combination; Esomeprazole; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Screening; Metronidazole; Middle Aged; Obesity, Morbid; Precision Medicine; Preoperative Care; Retrospective Studies; Young Adult | 2018 |
[Eradication Rates of 10-day Sequential Therapy for
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Republic of Korea; Tertiary Care Centers; Treatment Outcome | 2019 |
A novel hybrid first-line therapy for H. pylori eradication: results of a pilot study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors; Treatment Outcome | 2019 |
The current role of dual therapy for treatment of Helicobacter pylori: back to the future?
Topics: Amoxicillin; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2020 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2020 |
Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2023 |